Allogeneic CAR-T cell therapy is produced using CRISPR gene editing from cells donated by healthy individuals.

The firm saw an improvement in progression-free survival for patients on the ivonescimab regimen and a trend toward improved overall survival.

This is an ASCO Meeting Abstract from the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium. This abstract does not include a full text component.

Edgewise Therapeutics faces challenges with DMD/BMD programs, upcoming trial data concerns, and competitive risks.

Absci has entered the clinic with its AI-designed antibody, dosing first volunteers in a trial targeting TL1A for ...

This story contains details from testimony referencing suicide and suicidal ideations that are graphic, and some readers may ...

The FDA should now consider setting minimum thresholds for diverse inclusion, particularly in later-phase clinical trials. The FDA could also grant companies contingent approval (for example ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, ...

PR China bDrug Clinical Trial Center, Peking University Third Hospital, Beijing, PR China cDepartment of Clinical Research, State Key Laboratory of Oncology in South China, Guangdong Provincial ...

Over the past six months, Eli Lilly has earned significant wins over its Denmark-based rival and is still at it. Recent clinical trial results Eli Lilly released suggest that it is building a lead in ...

Capricor Therapeutics is seeking FDA approval for CAP-1002, targeting heart function in Duchenne Muscular Dystrophy patients.